Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyTwo SNPs of ATP-binding cassette B1 gene on the risk and prognosis of colorectal cancerOATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapyUGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.Quantitative evaluation of ABC transporter-mediated drug resistance based on the determination of the anticancer activity of camptothecin against breast cancer stem cells using TIRF.Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.
P2860
Q26775949-B2739B0B-0565-48AF-8A5D-536E8AA55ADBQ26851060-2073EDE7-8AE7-42C0-B8B5-678997773D0CQ35632295-749DC61D-3DC1-4707-BD58-385E4E7AAA5CQ35678729-5B3AA87C-D269-440F-865D-36C0498149B1Q37682812-173F32F2-EDAC-4FC3-9002-789DD108DD47Q38166454-A63C7513-3FA5-476A-A8A2-1138FF8BE781Q38414396-1B9B6E27-75FE-48C1-864D-8E1C9282FA6DQ38619018-C96C1E55-E133-4672-93C8-D967109E79F4Q38704025-B432557B-C529-47F1-967F-4B4E78ECC2DEQ38933314-0D148012-E0D5-46A5-B8A6-C5A8175FFCDFQ38937177-5351E04A-C12D-49E0-B394-0431B8E30D0DQ39140034-1B2C8351-88AD-4111-A3EA-D295CD958E79Q47665232-92000BD7-F0FB-42F2-82A3-9285FA36A14DQ50042411-0BE1253E-5326-4F3D-AC1B-34AE9D40D854Q51330694-484FB0DF-0651-4F59-A376-6C228D77BB16Q55280979-C03B8416-8F63-4B58-BF6B-5AC549E50573
P2860
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@en
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@nl
type
label
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@en
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@nl
prefLabel
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@en
Pharmacogenetics of ABC and SL ...... first-line FOLFIRI treatment.
@nl
P50
P1476
Pharmacogenetics of ABC and SL ...... g first-line FOLFIRI treatment
@en
P2093
Giuseppe Corona
Mario D'Andrea
P304
P356
10.1097/FPC.0B013E328364B6CF
P577
2013-10-01T00:00:00Z